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Objectives: The last decade witnessed great advances in the treatment of inflam-
matory bowel diseases (IBD) with the introduction of biologic therapies. Several eco-
nomic evaluations have been run to evaluate these treatments. The goal of this study 
was to analyze the existing evidences and key parameters included in IBD cost-
effectiveness studies. MethOds: A systematic literature review was conducted 
to identify economic evaluations of IBD therapy. Electronic databases (Embase and 
Medline) were used to identify full economic evaluations published from 2004 to 
2015. Cross-references of selected articles and gray literature search were also per-
formed to find additional publications. The health outcomes, costs, incremental 
cost-effectiveness (ICERs) and cost-utility ratios (ICURs) were analyzed. Results: 
The literature review allowed identifying 3,631 potentially relevant studies. Titles 
and abstracts screening allowed the selection of 53 articles. After assessment of 
those articles, 36 were found pertinent for the review. Four other studies were added 
from gray literature. Different treatments were evaluated including biologics (53%), 
immunosuppressants (3%), biologics and immunosuppressants combination (5%) 
and mesalamine (28%). Infliximab was the most common biologic treatment evalu-
ated (65%). In the cost-utility analyzes (88%), 35% had utility scores derived from IBD 
severity scores. The remaining studies used direct and indirect utility measurement 
methods, including EQ-5D (43%), standard gamble (33%), time trade off (25%) and 
visual analog scale (8%). Markov modeling, decision tree or a combination of both 
were used in 38%, 38% and 5% of the studies respectively. All studies included drug 
acquisition costs, 50% included treatment administration costs, 65% included hospi-
talization costs and 45% included surgical costs. cOnclusiOns: Several economic 
evaluations especially involving biologics were conducted in the past decade. This 
study showed that there are significant trends in key parameters, such as model 
development, utility measurements and costs included, which will be helpful in the 
feasibility of further cost-effectiveness analyses.
PGI30
shoulD sofosBuvIr-BasED all-oral trEatmEnt BE consIDErED In 
ElDErly chronIc hEPatItIs c PatIEnts?
Cortesi PA1, Ciaccio A1, Belleli G2, Rota M3, Rota M1, Conti S1, Mantovani LG4, Annoni G2, 
Strazzabosco M5
1University of Milano-Bicocca, Monza, Italy, 2University of Milan-Bicocca, Monza, Italy, Monza, 
Italy, 3University of Milan-Bicocca, Monza, Italy, 4University of Milano - Bicocca, Monza, Italy, 
5Yale University School of Medicine, New Haven, CT, USA
Objectives: A relevant proportion of patients affected by Chronic Hepatitis C(CHC) 
is older than 65 years. These patients have been undertreated in the past two dec-
ades, due to poor eligibility to interferon-containing regimens. New all-oral, inter-
feron-free antivirals may represent a valuable option for this population. Our aim 
was to assess the cost-effectiveness of sofosbuvir plus ledipasvir(SOF/LDV) therapy 
in genotype 1(G1) and 4(G4) CHC elderly patients. MethOds: A Markov model of 
CHC natural history was built. The model focuses on CHC patients older than 65 
years and assessed the impact of liver fibrosis (METAVIR F3 and F4), age and frailty 
phenotype, defined by Fried’s (not frail, pre-frail and frail), on the cost-effectiveness 
of SOF/LDV versus no treatment. The model estimated costs, Life Years and Quality-
Adjusted Life Years (QALY) using the lifetime time horizon and the National Health 
System perspective. Results were presented as incremental cost-effectiveness ratios 
(ICERs) per QALY gained. Results: The cost-effectiveness of all-oral and IFN-free 
treatment regimen in HCV elderly patients is influenced by all three parameters 
assessed in our simulation. ICER was higher in lower fibrosis stages and increased 
with age and frailty phenotype. In F3 and F4 patients ICER was below 40,000 € /QALY 
up to age 83.3 and over 85 years in non-frail patients, up to age 79.5 and 82.5 in pre-
frail and up to age 76.5 and 79.5 in frail, respectively. The ICER was more sensitive 
to drug price and SVR probability. Further, the mortality rate not-liver related had 
a higher impact in the not-frail patients. cOnclusiOns: Age and fibrosis stage 
are not enough to assess the cost-effectiveness of anti-HCV treatment in elderly 
subjects. A careful assessment of the patient geriatric status should be mandatory, 
especially in patients older than 75 years, to better allocate the resources available 
and to prioritize the access to the treatment.
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Objectives: A published economic model of biological therapies for moderate to 
severe Crohn’s disease was used recently in the National Institute for Health and 
Care Excellence (NICE) technology appraisal for vedolizumab. The objective of this 
study was to identify key drivers of cost effectiveness in Crohn’s disease. MethOds: 
The published economic model was reconstructed using data from Bodger et al. 
(2009), supplemented by the vedolizumab NICE submission. Costs were updated to 
2013/14, and efficacy data were taken from the submission as this used a recent 
network meta-analysis (NMA). The reconstructed model omitted aspects of the 
vedolizumab submission that were heavily criticised by the Evidence Review Group 
(ERG). The deterministic incremental cost-effectiveness ratios (ICER) from the re-
constructed model were compared with those reported for the published model. A 
one-way sensitivity analysis of vedolizumab versus standard care was performed 
using the same assumptions as the submission base case, and the outputs of both 
models were compared. Results: For the base case results, Bodger et al. reported 
ICERs versus standard care of £19,050 for infliximab and £7,190 for adalimumab. In 
contrast, the reconstructed model reported ICERs of £54,077 and £31,210. These are 
similar to the results from the vedolizumab submission model, indicating that the 
differences are principally due to the use of NMA data from the submission. The key 
drivers were broadly similar between the reconstructed model and the submission 
was conduced from the National Public Health System (SUS) perspective. A Markov 
model was constructed using TreeAge Software to simulate the clinical of patients 
that undergo to liver transplantation, with 10 years of horizontal time. In the model, 
the expected cost and effectiveness were compared between EVR+rTAC versus TAC. 
In both treatment strategies, there were the possibilities of rejection, graft loss, renal 
failure and renal transplantation and death. The probabilities were taken from a 
multicenter clinical randomized study that followed the patients for 2 years after 
liver transplantation using TAC or EVR+rTAC. The chosen endpoints were rejection, 
graft loss and renal dysfunction (creatinine clearance< 60, MDRD4, mL/min/1.73m2). 
The estimative of 525 patients that will need a liver transplantation at SUS per year 
was used in Monte Carlo microssimulation, based on 2014 data. Results: EVR+rTAC 
strategy preserved 26.2% of renal function, decreased 7.2% of rejections, avoided 1.9% 
of renal transplantation and 7.8% of liver re-transplantation. The treatment with 
EVR+rTAC increased the annual public costs in $172.78 (the first year) and $361.08 
(the first two years) per patient. The simulation of EVR+rTAC only in patient who will 
have renal dysfunction after liver transplantation resulted in an annual median cost 
of $251.02 per patient per complication avoided, 37% less than when all patients used 
TAC ($1,312.32). The Monte Carlo microsimulation for 525 potential patients resulted 
in a cost of $1,072.51 per year per patient free of complications treated with EVR+rTAC, 
18% less than when all patients were treated with TAC. cOnclusiOns: Everolimus 
associated with reduced tacrolimus doses is cost-effective when analyzing the renal 
dysfunction avoided in the liver transplantation.
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Objectives: The prevalence of liver disease is increasing and often remains unde-
tected until the late stages.The study estimated cost-effectiveness of an innovative 
diagnostic pathway (IDP) targeting adults with risk factors of non-alcoholic fatty 
liver disease (NAFLD) from an NHS England perspective. MethOds: Economic eval-
uation compared IDP (algorithm applied in a general practice to identify adults with 
risk factors for NAFLD, then stratifying disease severity using a Fibroscan to test liver 
stiffness, followed by hepatologist-led treatment appropriate to disease stage) with 
standard care (SC, hepatology referral due to abnormal LFTs). Probabilistic modelling 
of NAFLD progression was combined with the diagnostic accuracy of IDP and SC 
estimated from a feasibility study, incorporating fibrosis stages (no/mild disease, 
moderate liver disease, compensated cirrhosis) split into health states: ‘identified’ 
and ‘unidentified’ risk factor/disease. Advanced NAFLD states were: decompensated 
cirrhosis, hepato-cellular carcinoma, liver transplant and death. Transition prob-
ability, utility and resource use data were based on uptodate UK sources, or – if not 
possible - on expert panel responses to indicate early disease management and 
its estimated effectiveness. Lifetime Markov cohort modelling with starting age 
of 68, annual cycle, and costs and utilities discounted at 3.5%-rate, was applied. 
Cost-effectiveness planes and cost-effectiveness acceptability curves, based on 
5000-sample Monte Carlo simulation, were constructed. Results: IDP yielded 
increased QALYs (95% CI) ( 0.24 (-0.18, 0.63)) and reduced costs (-£2661 (-10831, 
7099), compared with SC, with 69.7%-probability of dominance, and 88.3%-prob-
ability of cost-effectiveness at £20000/QALY threshold. The results were associated 
with high levels of uncertainty due to the poor quality of data available for transition 
probabilities in early liver disease. cOnclusiOns: Indicative economic evaluation 
showed that IDP may be cost-effective, compared with standard care. Due to large 
uncertainty of model input parameters and no data around progression and man-
agement of early liver disease, further studies on IDP implementation are needed.
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Objectives: Hepatitis C Virus(HCV) is a growing health problem in the world. The 
aim of this study is to estimate a cost-effectiveness of a triple therapy(TT) with 
simeprevir compared to a TT with telaprevir for the previously treated with double 
therapy HCV patients in Kazakhstan. MethOds: Markov model build in Tree-Age 
Pro 2013 was used for cost-effectiveness analysis from the perspective of Ministry 
of Health with a lifetime horizon. The model consists of two phases: (1)period of 
treatment with TT (48 weeks), and (2)lifetime follow-up. Cycle of the first phase is 
measured in weeks, the second - in years of life. The effectiveness was determined 
by the sustained virologic response(SVR), defined as HCV RNA< 25 IU/mL after 12 
weeks after completion of antiviral therapy. Effectiveness data was obtained from 
published RCTs, the direct costs adjusted to local settings are expressed in 2015 
Kazakhstani Tenge(KZT). The average age of reference patient was 40 years. All 
future costs and health outcomes(QALYs) were discounted for 3% per year. One 
way sensitivity analysis was performed to test the robustness of model. Results: 
Over 30-year stimulation of the model, TT with simeprevir incurred 6.81mln KZT 
and 24.2053 QALYs per patient, whereas TT with telaprevir incurred 10.98mln KZT 
and 24.2593 QALYs per patient. There was insignificant difference (p> 0.05) in health 
outcomes between options. TT with simeprevir is expected to save 4.17mln KZT per 
patient if replases TT with telaprevir. The results of model were robust to changes 
in key parameters. cOnclusiOns: The introduction of simeprevir as part of TT for 
HCV patients that had null or partial responce to previous double antiviral therapy 
seems to be a cost-effective option in Kazakhstan from the perspective of Ministry 
of Health compared to current TT with telaprevir. These findings may better inform 
decision makers regarding formulary inclusion and reimbursement.
